Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04735198 | Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.(TNE-IDC-COLE) | recruiting | N/A | 100 | Hospital Universitari de BellvitgeOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT02840149 | SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors | completed | Phase 3 | 45 | Jewish General HospitalOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06973824 | A Twenty-years' Experience in Pituitary Disease.(TYEPDD) | recruiting | — | 1,600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02246127 | Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor(SEQTOR) | completed | Phase 3 | 141 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 8 | May 11, 2025 | clinicaltrials |
| NCT03289741 | A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | completed | Phase 4 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06121622 | Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours(3DPanNET) | recruiting | — | 70 | IRCCS San RaffaeleOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06456723 | Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.(FETONET) | completed | Phase 1 / Phase 2 | 56 | Imperial College LondonOTHER | 0 | May 1, 2025 | clinicaltrials |
| NCT04584866 | Semi-sitting Versus Supine Position in Endoscopic Skull Base Surgery(PosESS) | completed | N/A | 54 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05167071 | HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | active not recruiting | Phase 1 | 53 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06874426 | The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction(Endo-Olfact) | recruiting | — | 154 | Universitaire Ziekenhuizen KU LeuvenOTHER | 3 | Apr 23, 2025 | clinicaltrials |
| NCT06937112 | 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis | recruiting | — | 20 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05734430 | Genetics of Appendix Cancer Study(GAP) | recruiting | — | 700 | Andreana Holowatyj, PhD, MSCIOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04893759 | A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors | terminated | Phase 1 | 2 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT03667092 | Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor(GENEBIOLuNET) | completed | N/A | 47 | University Hospital, ToulouseOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04464122 | Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)(REBORN) | recruiting | — | 60 | University of Roma La SapienzaOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06056362 | Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 80 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06901856 | Endoscopic Resection for Small Rectal Neuroendocrine Tumors | not yet recruiting | N/A | 120 | Guangdong Provincial People's HospitalOTHER | 0 | Mar 30, 2025 | clinicaltrials |
| NCT04986085 | Nutrition in Gastroenteropancreatic Neuroendocrine Tumor(NUTRIGETNE) | completed | — | 399 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05804331 | The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study(ANZ UGI) | recruiting | — | 500 | Western Sydney Local Health DistrictOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT02348749 | 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies | completed | Phase 1 / Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06853457 | A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases | completed | — | 257 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Mar 3, 2025 | clinicaltrials |
| NCT06855095 | Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial(ATSA) | recruiting | Phase 2 / Phase 3 | 39 | The Netherlands Cancer InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02464007 | Study of rSIFN-co for Patients With Advanced Solid Tumors | terminated | Phase 1 | 7 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05053854 | PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours(PARLuNET) | recruiting | Phase 1 | 24 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT02795858 | A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors | completed | Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06242119 | Clinical Application of the J-PET Scanner Prototype(JPET2Clinic) | recruiting | — | 25 | Jagiellonian UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04438304 | A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) | completed | Phase 2 | 45 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05246319 | Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors(TEGRELE) | completed | — | 50 | Laurent BRUNAUDOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02842749 | Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | completed | Phase 4 | 61 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04432532 | Neuroendocrine and Adrenal Tumors(NETAT) | withdrawn | — | 0 | University of PennsylvaniaOTHER | 0 | Feb 10, 2025 | clinicaltrials |
| NCT05680675 | Dual-Tracer Theranostic PET | completed | N/A | 50 | University of UtahOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT02691078 | Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors | completed | Phase 2 | 15 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT04197310 | Cabozantinib and Nivolumab for Carcinoid Tumors | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT05013957 | Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study(NEMESIs) | completed | — | 32 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04696042 | Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs(AIM-NETs) | completed | — | 71 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04524442 | Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | completed | Phase 4 | 42 | Advanced Accelerator ApplicationsINDUSTRY | 4 | Jan 24, 2025 | clinicaltrials |
| NCT06790056 | Efficacy of Endoscopic Band Ligation (DEBL) for Duodenal Neuroendocrine Neoplasms(dNENs)(DEBL) | completed | — | 50 | Asian Institute of Gastroenterology, IndiaOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06679816 | Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors | recruiting | Phase 4 | 882 | Beijing Tiantan HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT02489604 | Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors(LUNET) | terminated | Phase 2 | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT02736500 | Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors(LuX) | completed | Phase 1 / Phase 2 | 39 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT03980925 | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | completed | Phase 2 | 37 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT03095274 | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin(DUNE) | completed | Phase 2 | 126 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06764368 | Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors | not yet recruiting | Phase 2 | 39 | Beijing Chest HospitalOTHER | 0 | Jan 8, 2025 | clinicaltrials |
| NCT02724540 | Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver | completed | Phase 2 | 162 | Abramson Cancer Center at Penn MedicineOTHER | 4 | Jan 6, 2025 | clinicaltrials |
| NCT05255133 | A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment(Liquid-NET) | completed | N/A | 22 | Universiteit AntwerpenOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT03278379 | Avelumab in G2-3 NET(NET-002) | completed | Phase 2 | 17 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04649580 | United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting(PREF-NET) | completed | — | 80 | IpsenINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 20, 2025source: clinicaltrials